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Abstract
Background: The tuberculin skin test (TST) is still the standard test for detecting latent infection by M tuberculosis
(LTBI). Given that the Brazilian Health Ministry recommends that the treatment of latent tuberculosis (LTBI) should be
guided by the TST results, the present study sets out to describe the coverage of administering the TST in people
living with HIV at two referral health centers in the city of Recife, where TST is offered to all patients. In addition,
factors associated with the non-application of the test and with positive TST results were also analyzed.
Methods: A cross-sectional study was carried out with HIV patients, aged 18 years or over, attending outpatient
clinics at the Correia Picanço Hospital/SES/PE and the Oswaldo Cruz/UPE University Hospital, who had been
recommended to take the TST, in the period between November 2007 and February 2010. Univariate and
multivariate logistic regression analyses were carried out to establish associations between the dependent variable -
taking the TST (yes/no), at a first stage analysis, and the independent variables, followed by a second stage analysis
considering a positive TST as the dependent variable. The odds ratio was calculated as the measure of association
and the confidence interval (CI) at 95% as the measure of accuracy of the estimate.
Results: Of the 2,290 patients recruited, 1087 (47.5%) took the TST. Of the 1,087 patients who took the tuberculin
skin test, the prevalence of TST ≥ 5 mm was 21.6% among patients with CD4 ≥ 200 and 9.49% among those with
CD4 < 200 (p = 0.002). The patients most likely not to take the test were: men, people aged under 39 years,
people with low educational levels and crack users. The risk for not taking the TST was statiscally different for
health service. Patients who presented better immunity (CD4 ≥ 200) were more than two and a half times more
likely to test positive that those with higher levels of immunodeficiency (CD4 < 200).
Conclusions: Considering that the TST is recommended by the Brazilian health authorities, coverage for taking the
test was very low. The most serious implication of this is that LTBI treatment was not carried out for the
unidentified TST-positive patients, who may consequently go on to develop TB and eventually die.
Background
The HIV epidemic has had serious consequences around
the world and especially in developing countries. One of
the gravest of these has been an increase in the incidence
of tuberculosis (TB) [1]. In the population not infected
with HIV, 5% of those infected with M. tuberculosis may
develop primary TB within the first two years following
exposure and another 5% may develop post-primary TB
later in life. By contrast, co-infected individuals stand a
5-10% chance each year of developing TB [2,3].
In recent years, considerable investment has been made
available for research into tuberculosis control programs,
including the introduction of various strategies to contain
the advance of this epidemic [1,4,5]. However, despite the
adopted strategies, there has been an increase in the preva-
lence of HIV, which has resulted in a rise in the incidence
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any medium, provided the original work is properly cited.of TB [6]. Tuberculosis is still the leading cause of death in
HIV positive patients in various parts of the world, espe-
cially in countries where the disease is rife and resources
are limited [7-9].
Clearly, the risk of developing TB is lower in patients
infected with HIV who receive HAART. However, TB
still occurs even when patients are undergoing HAART
[8,10-13]. In countries with a low prevalence of TB/HIV
co-infection the use of HAART is associated with a
marked reduction in the incidence of many opportunistic
infections [10,14-16], while in countries with a high pre-
valence of co-infection it is still unclear whether this pro-
tective effect occurs [17]. To establish a substantial
impact on the incidence of TB, it would be necessary to
begin HAART early in the course of HIV infection, with
a high level of coverage and adherence [18].
The effectiveness of LTBI treatment with isoniazid in
people living with HIV has been reported since the last
decade. The majority of clinical trials and prospective
cohort studies have shown that treatment with isoniazid
for six or 12 month periods prevents tuberculosis and is
safe in people infected with HIV and with TST ≥ 5m m
[19-25]. Based on the existing evidence, LTBI treatment
with daily doses of isoniazid for six or nine months is
recommended in individuals living with HIV [26,27].
HIV positive patients with a reactive TST (≥ 5m m )h a v e
a significantly higher risk of developing full-blown TB than
those who do not react (< 5 mm) [28-30]. A systematic
review of randomized clinical trials shows that the treat-
ment of LTBI based on a reactive TST reduces the risk of
active TB in patients with HIV [31]. Evidence such as this
provides grounds for the use of TST and the subsequent
treatment of LTBI [32,33].
The tuberculin skin test (TST), based on the detection
of a delayed hypersensitivity reaction to Purified Protein
Derivative (PPD) is still the standard test for detecting
infection by M. tuberculosis. In order to conduct this test,
two visits are needed, one for the inoculation and another
to read and interpret the test results [32,33], Although it is
a simple test requiring only low-cost materials, with no
need for the presence of a laboratory specialist and is
extensively used in contexts where resources are limited,
epidemiological studies and annual investigations [34,35]
have nonetheless shown that there are practical difficulties
associated with administering the TST. Coverage differ-
ences exist for administering the TST in different health
services, suggesting that the motivation of health staff is
important when caring for HIV-positive patients [28]. On
the other hand, the low sensitivity and specificity of the
TST has cast some doubt on its performance and, as a
consequence, it has been less requested by attending
physicians [12,28]. There is also concern that LTBI treat-
ment using isoniazid alone may lead to resistance to this
drug [36,37] as well as potential side-effects [24,38,39].
However, TST is still used worldwide for LTBI screening
in individuals with HIV/AIDS, including developing coun-
tries [40].
From a clinical perspective, the diagnosis and treatment
of LTBI are important measures in reducing the risk of
progression to active TB and its associated complications
[6]. It is believed, that where an effective logistical system
for acquiring and distributing the TST and isoniazid
(INH) was established, both physicians and patients would
be encouraged to take the TST and read the results
[17,26,41].
Given that the Brazilian Health Ministry recommends
that LTBI treatment should be guided by the results of the
TST [42-44] the present study aims to describe the cover-
age of administrating the TST in people living with HIV/
AIDS, attended at two health centers in the city of Recife,
where TST is available. In addition the factors associated
with the non-application of the test, and with a positive
TST result in patients infected with HIV, were also
analyzed.
Methods
Study Population, Recruitment, and Survey Methods
A cross-sectional study was carried out with people living
with HIV/AIDS, aged 18 years or over, attending outpati-
ent facilities at the Correia Picanço Hospital/SES/PE and
the Oswaldo Cruz/UPE University Hospital, which are
referral services for HIV/AIDS in the city of Recife, Brazil,
between November 2007 and February 2010.
Patients were excluded if they had a previous history
of or were undergoing treatment for tuberculosis or
LTBI.
Patients were first informed of the purpose of the
research and, once they had agreed to participate, were
asked to sign the terms of free informed consent. Informa-
tion was gathered by way of interviews and the application
of a questionnaire designed specifically for this study. In
addition to the questionnaire, a special form was used by
the principal researcher to obtain data from medical
records.
The tuberculin skin test was carried out by trained tech-
nicians at each health center, using the Mantoux techni-
que. A 0.1 ml dose of PPD (purified protein derivative)R T
23, was applied intradermally in the middle third of the
left forearm. The test was considered to be reactive when
an induration ≥ 5 mm was detected, 72 hours after admin-
istering the PPD.
In view of the known difficulty of incorporating this
test into clinical practice, the research plan included a
lecture for attending physicians, at each of the services
covered by the study. The talk was delivered by a specia-
list in pneumology with extensive experience in tubercu-
losis, in an attempt to raise awareness among physicians
of the importance of performing the TST and treating
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Talks were also arranged for patients at the two centers
as a way of informing them of the risk of contracting TB
and of the importance of the TST in screening for LTBI.
The study was carried out in two stages. In the first
stage, involving all the patients in the cohort making up
the study sample, the coverage of TST testing was cal-
culated and factors associated with not taking the test
were investigated; in a second stage factors associated
with testing positive on the TST were analyzed only for
the group of patients who actually took the test.
Definition of Variables
In the first analysis, the dependent variable was having
taken the tuberculin skin test, considering patients who
did not take the TST as cases and those who did as the
control group.
The independent variables examined were: biological
variables (sex and age), socio-demographic factors (place
of residence, years of schooling, hospital attended), life
habits (alcohol consumption - categorized as abstinent,
light drinker, heavy drinker, and people undergoing alco-
hol dependence treatment -, smoking - categorized as
non-smoker, former smoker, and smoker -, marijuana use,
cocaine use, and crack use) and clinical variables (history
of contact with tuberculosis, body mass index (BMI), use
of HAART, time on HAART, presence of AIDS, CD4
T-lymphocyte count)
For the alcohol consumption variable, patients were
classified as teetotal if they reported that they never drank
or drank less than eight units a year; a light drinker if they
drank a maximum of two days a week, without exceeding
ten units per month; a heavy drinker if they drank in
excess of five doses a day at least 3 to 4 days a week, and
as dependent if they were undergoing treatment. For the
smoking variable, non-smokers were considered to be
those who had never smoked in their life, former smokers
those who had quit smoking at least six months before the
date of inclusion in the study; and smokers those who
were smoking on the day they entered the study or who
had quit less than six months before this date.
In the second analysis, the dependent variable relating to
the result of the tuberculin skin test was classified on the
b a s i so fp a t i e n t sw h or e a c t e dt ot h eT S T( ≥ 5m m )a n d
the controls, which did not react (0-4 mm). The indepen-
dent variables were the same used for the first stage.
Data Analysis
For both stages of the study, the c
2 test was used to test
the statistical significance of associations and the p value
was calculated. A univariate analysis was conducted of
the association between the dependent variable and the
independent variables, using the odds ratio (OR) as the
measure of association (OR) and a confidence interval
(CI) of 95% as the measure of accuracy of the estimate.
Analysis of multivariate logistic regression used the back-
ward stepwise method for selecting variables, thereby
including in the model all variables associated with fail-
ure to conduct the tuberculin skin test for the first stage,
and with a positive TST for a second stage, with a level
of significance of p < 0.25 in the univariate analysis. The
final model retained variables whose association with fail-
u r et oc o n d u c tt h eT S Tf o rt h ef i r s ts t a g e ,a n dw i t ha
positive TST for a second stage were statistically signifi-
cant at a level of p ≤ 0.05.
The study was approved by the Ethics Committee at
the Federal University of Pernambuco for research
involving human beings (SISNEP FR-067159/CAAE-
0004.1.172.106-05/REGISTRO CEP/CCS/UFPE 254/05).
Results
Between November 2007 and February 2010, 2,290
patients were recruited for the study. Of these, 1,425
(62.2%) were male and the mean age of the patients was
39.36 years. Most of the patients included in the study
were non-white (73.4%), lived as part of a family (80.8%)
and did not have a steady partner (53.5%). 87.8% were lit-
erate and 58.6% had up to nine years of schooling. In rela-
tion to life habits, 38.3% consumed alcohol, 27.3% used
marijuana, 9.2% cocaine, 6.9% crack and 55.1% were
smokers.
A total of 641(28%) patients related contact with
tuberculosis, while information on close contact with
smear positive TB was unavailable.
Of the 2,290 patients, 1087 (47.5%) took the tuberculin
skin test (TST) (Figure 1). The mean age of the group who
took the TST was 40.4 years (± 0.3) compared with 38.4
years (± 0.3) for the group who did not. The difference
between these two means was not statistically significant.
Figure 1 Flowchart of the study population.
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variables studied, chi square and p value.
Tables 3 and 4 show the results of the univariate analysis
of the association between biological variables (sex, age),
sociodemographic factors (place of residence, years of
schooling, hospital attended), life habits and clinical vari-
ables (history of contact with tuberculosis, body mass
index (BMI), use of HAART, time on HAART, presence
of AIDS, T-lymphocyte CD4 count) and the two outcomes
studied, adherence to TST and TST reactivity.
Factors associated with not taking the TST remaining in
the final model of the multivariate analysis were: being
m a l e ,a g e du pt o3 9y e a r s ,p l a c eo fr e s i d e n c e( l i v i n gi n
cities in the interior of the state), being attended at the
HCP, being a crack user, less time on HAART, presence
of AIDS and a CD4 count ≥ 200 (Table 5).
T h er e s u l t so ft h es e c o n ds t a g eo ft h es t u d ys h o w e d
that, of the 1,087 patients who took the TST, 20.4% (222)
tested positive (TST ≥ 5 mm). The mean TST was 3.9
mm (min = 0; max = 48 mm). The prevalence of TST
≥ 5 mm was 21.6% among patients with CD4 ≥ 200 and
9.49% among patients with CD4 < 200 and this difference
was statistically significant (p = 0.002).
The mean CD4 count was 447.2 cells/mm3 in the
group of patients who did not react to the TST and 557.9
in the group who did react and this difference was statis-
tically significant (p < 0.001).
In the final multivariate model the following factors
were associated with a reactivity to the TST: place of
r e s i d e n c e( l i v i n gi nt h eM e t r o p o l i t a nR e g i o n ) ,b e i n g
attended at the HCP, less than ten years of schooling,
crack use and a CD4 count of ≥ 200 (Table 5).
Discussion
In the present study, 52.5% of patients did not take the
TST, despite the fact that it is recommended by the Bra-
zilian Ministry of Health. The non-adherence to TST
was associated with being male, being younger, living in
the interior of state of Pernambuco, being attended at
t h eH C P ,b e i n gau s e ro fc r a c k ,l e s st i m eo nH A A R T ,
presence of AIDS and a CD4 count < 200. Among the
patients who took the TST, 20.4% (222) tested positive
(TST ≥ 5 mm). TST positivity was associated with crack
use, CD4 ≥ 200, being attended at the HCP, having less
years of schooling and living in the Metropolitan Region
of the state of Pernambuco.
Reports on TST adherence have varied from a rate of
30%, for not taking the test in a country with a low pre-
valence of tuberculosis [28], and a rate similar to that
encountered in the present study (50.2%) from a study
also carried out in Brazil [45].
It was observed that the incorporation of the TST into
routine care at the two centers was not sufficient to
ensure that attending physicians actually requested the
test, or indeed that patients would take it, even after talks
had been given to raise the awareness of professionals
and patients alike on the need and pertinence of the TST
for recommending LTBI treatment. This situation
Table 1 Distribution of biological and socio-economic characteristics of people living with HIV by adherence to TST
and TST reactivity, Recife 2007-2010
VARIABLES WITH TST WITHOUT TST Chi
2 Pr TST ≥ 5 mm TST = 0-4 mm Chi
2 Pr
n% n % n % n %
Biological variables
Sex 12.2 < 0.001 0.1 0.747
Female 451 41.5 414 34.4 90 40.5 361 41.7
Male 636 58.5 789 65.6 132 59.5 504 58.3
Age 19.7 < 0.001 0.0 0.905
40 years or over 569 52.3 518 43.1 117 52.7 452 52.3
Up to 39 years 518 47.7 685 56.9 105 47.3 413 47.7
Socio-demographic variables
Place of Residence 18.9 < 0.001 4.3 0.114
Recife 496 45.8 516 43.4 89 40.1 407 47.3
Metropolitan Region 462 42.7 460 38.7 108 48.6 354 41.2
Interior 124 11.5 213 17.9 25 11.3 99 11.5
Years of schooling 10.4 0.001 6.2 0.013
≥ 10 years 487 44.8 459 38.2 83 37.4 404 46.7
Up to 9 years 600 55.2 744 61.8 139 62.6 461 53.3
Hospital attended 17.4 < 0.001 13.0 < 0.001
HUOC* 474 43.6 422 35.1 73 32.9 401 46.4
HCP* 613 56.4 781 64.9 149 67.1 464 53.6
* HCP - Correia Picanço Hospital; HUOC - Oswaldo Cruz University Hospital.
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low rate of testing is a consequence of the unavailability
of TST at health care services attending patients with
HIV/AIDS [4,27,41]. It is important to clarify this ques-
tion, since the treatment of LTBI depends essentially on
the administration of the TST [41,42,45-47], and in Brazil
this is recognized as an indicator of the quality of the ser-
vice [41].
A recent WHO guideline recommends that in resource-
limited countries the TST might not be required for start-
ing LTBI treatment for people living with HIV, since
screening for active TB has been carried out [48]. How-
ever, the Brazilian Ministry of Health does not adopt the
criterion of performing LTBI treatment for people living
with HIV when a TST has not been performed or the
result is unknown, based on the grounds that the benefit
is greater for those with TST reactor (≥ 5m m ) ,a sd e m o n -
strated by a systematic review [31]. The exceptions are
cases of people living with HIV that relate a history of
recent contact (less than two years) with TB bacillus, or
those who present radiographic imaging of sequelae of
pulmonary TB with no previous history of TB treatment
[42,44].
The levels of adherence to TST in this study are of
considerable concern, since a prevalence of TST ≥ 5m m
of 20.5% was encountered among those who took the
Table 2 Distribution of habits and clinical characteristics of people living with HIV by adherence to TST and TST
reactivity, Recife 2007-2010
VARIABLES WITH TST WITHOUT TST Chi
2 Pr TST ≥ 5 mm TST = 0-4 mm Chi
2 Pr
n% n % n % n %
Habits
Alcohol Consumption 0.3 0.591 3.9 0.048
Non-drinker 665 61.2 666 62.3 123 55.4 542 62,7
Drinker 422 38.8 403 37.7 99 44.6 323 37.3
Smoking 2.5 0.113 7.6 0.006
No 506 46.6 519 43.2 85 39.3 421 48.7
Yes 581 53.4 681 56.8 137 61.7 444 51.3
Marijuana Use 7.6 0.006 12.8 < 0.001
No 820 75.4 842 70.3 147 66.2 673 77.8
Yes 267 24.6 356 29.7 75 33.8 192 22.2
Crack use 8.5 0.003 20.3 < 0.001
No 1030 94.80 1099 91.7 197 88.7 833 96.3
Yes 57 5.20 100 8.3 25 11.3 32 3.7
Cocaine use 7.2 0.007 5.9 0.015
No 1006 92.50 1070 89.3 197 88.7 809 96.5
Yes 81 7.50 128 10.7 25 11.3 56 6.5
Clinical variables
History of Contact with Tuberculosis 1.8 0.174 2.3 0.133
No 762 70.5 873 73.1 146 66.4 616 71.5
Yes 319 29.5 322 26.9 74 33.6 245 28.5
BMI 12.7 < 0.001 0.5 0.492
Not malnourished 1010 93.1 997 88.7 209 94.1 803 92.8
Malnourished 75 6.9 127 11.3 13 5.9 62 7.2
On HAART 0.0 0.918 4.9 0.026
No 240 22.2 246 22.3 61 27.7 179 20.7
Yes 843 77.8 855 77.7 159 72.3 684 79.3
Time on HAART 38.8 < 0.001 2.8 0.096
Less than 1 year 139 12.8 202 23.3 21 9.5 118 13.6
One year or more 948 87.2 653 76.3 201 90.5 747 86.4
AIDS 24.7 < 0.001 2.9 0.087
No 189 17.9 117 10.5 47 21.9 142 16.8
Yes 869 82.1 1002 89.5 168 78.1 701 83.2
CD4 67.1 < 0.001 10.7 0.001
< 200 137 12.6 276 26.7 13 7.6 124 17.9
≥ 200 950 87.4 758 73.3 157 92.4 570 82.1
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patients live in a region with a high prevalence of TB.
Pernambuco has an incidence coefficient of 47.6 per
100,000 inhabitants for tuberculosis and this is consid-
ered to be the highest in the Northeast region. Recife, the
city where this study was developed is the Brazilian capi-
tal with the largest rates of new tuberculosis cases in the
country (132 cases per 100,000 inhabitants) and the TB
mortality rate was the greatest in the country, 7.7 per
100,000 inhabitants [46].
Two other studies carried out in Brazil found a preva-
lence of 24.8% [45] and 34.0% [17] for a positive reaction
to the TST in HIV-positive individuals. At present in
Brazil, around 50 million individuals are infected with
M. tuberculosis and roughly 14% of tuberculosis cases are
related to HIV [49]. This may explain the high rates for
positive TST results. A lower prevalence has been reported
in Atlanta (2.5%) and in Switzerland (9.4%), which lie in
regions considered to have a low prevalence of tuberculo-
sis [28,50]. Moreover, a percentage of 20.5 of TST positiv-
ity would suggest that of the 1203 individuals who did not
take the TST, around 20% could also be positive. There-
fore, it is possible to estimate that 245 patients lost the
opportunity of being diagnosed with and treated for LTBI.
Furthermore, considering that among the 222 patients
with positive TST results, 21 (9.5%) have been diagnosed
with active tuberculosis, it is possible to estimate that
around 23 patients could have been diagnosed and treated
for active TB.
The final multivariate model of factors associated with
not taking the TST showed that men and younger people
presented a 48% and 28% greater likelihood of not taking
the test, respectively. This would mean that adherence to
the TST was less frequent among those with a greater
likelihood of developing of tuberculosis [30,31].
Of the life habits, only crack use remained in the final
multivariate model, which is in accordance with the
hypothesis that drug use impedes adherence to health care
procedures. As expected, fewer people living in the interior
of the state took the TST, possibly due to the distances
between their homes and the health centers, which are
located in the state capital,R e c i f e .N o tu n d e r g o i n gt h e
TST was also associated to the diagnosis of AIDS, to less
than one year on HAART and a CD4 count ≥ 200. Elzi et
al. (2007) also found that the TST was performed more
frequently among patients with CD4+ cell counts of < 200
cells/mL [28]. This would suggest that the more severe
patients are more frequently tested for LTBI. The most
aggravating factor within this group of patients is that they
have a greater chance of having a non-reactive response to
TST, even when present. Mycobacterium tuberculosis is an
intracellular pathogen that principally inhabits the macro-
phages. Protective immunity from M. tuberculosis depends
on the integrity of the cellular immune system. HIV infec-
tion, by damaging the immunity mediated by cells, is the
most potent known risk faction for reactivation of latent
TB [3]. However, it is often not possible to detect this
infection using the TST and some authors consider a
Table 3 Univariate analysis of the association between biological and socio-economic variables and adherence to TST
and TST reactivity, Recife 2007-2010
VARIABLES NOT TAKING TST TST ≥ 5m m
OR (CI 95%) P OR (CI 95%) P
Biological variables
Sex
Female 1.0 - 1.0 -
Male 1.35 (1.14-1.60) < 0.001 1.05 (0.87-1.70) 0.250
Age
40 years or over 1.0 - 1.0 -
Up to 39 years 1.45 (1.23-1.71) < 0.001 0.98 (0.73-1.32) 0.902
Socio-demographic variables
Place of Residence
Recife 1.0 - 1.0 -
Metropolitan Region 0.95 (0.80-1.14) 0.63 1.40 (1.01-1.91) 0.038
Interior 1.65 (1.28-2.12) < 0.001 1.15 (0.70-1.90) 0.569
Years of schooling
≥ 10 years 1.0 - 1.0 -
Up to 9 years 1.31 (1.11-1.55) 0.001 1.47 (1.08-1.98) 0.013
Hospital attended
HUOC* 1.0 - 1.0 -
HCP* 1.43 (1.21-1.70) < 0.001 1.76 (1.29-2.40) < 0.001
* HUOC - Oswaldo Cruz University Hospital; HCP - Correia Picanço Hospital;
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ficiency to be a false negative [51-53]. The main implica-
tion of this is that treatment of LTBI is jeopardized in
patients with a non-reactive TST caused by immunodefi-
ciency. It is thus recommended that other factors be taken
into account, such as the rate of infection or disease in the
community, demographic data, a history of exposure and
abnormalities in the chest X-ray [42]. These factors could
help to identify patients with a high risk of developing
tuberculosis, for whom LTBI treatment should be consid-
ered regardless of the TST result, given that there is as yet
no valid substitute for the TST in patients with HIV [54].
One striking finding of the present study is the fact
that the frequency of TST was different at the two cen-
ters (p < 0.001). This suggests different levels of involve-
ment with TB control for the two teams. In particular,
it stresses the role of the attending physician in this pro-
cess, as it is this member of the team who, in Brazil,
decides whether to initiate treatment of LTBI or not
[23], and who is thus responsible for encouraging
patients to take the TST when recommended. However,
attention should be drawn to the nurses’ role who is
generally the team member that administers the TST,
and who schedules the return visit to read the test.
Table 4 Univariate analysis of the association between habits and clinical variables with adherence to TST and TST
reactivity, Recife 2007-2010
VARIABLES NOT TAKING TST TST ≥ 5m m
OR (CI 95%) P OR (CI 95%) P
Habits
Alcohol Consumption
Non-drinker 1.0 - 1.0 -
Drinker 0.95 (0.80-1.13) 0.591 1.35 (1.00-1.82) 0.048
Smoking
No 1.0 - 1.0 -
Yes 1.14 (0.96-1.34) 0.113 1.53 (1.13-2.07) 0.006
Marijuana Use
No 1.0 - 1.0 -
Yes 1.30 (1.08-1.56) 0.006 1.79 (1.30-2.46) < 0.001
Crack use
No 1.0 - 1.0 -
Yes 1.64 (1.17-2.30) 0.004 3.30 (1.91-5.70) < 0.001
Cocaine use
No 1.0 - 1.0 -
Yes 1.48(1.11-1.98) 0.008 1.83(1.11-3.01 < 0.001
Clinical variables
History of Contact with Tuberculosis
No 1.0 - 1.0 -
Yes 0.88(0.73-1.06 0.175 1.27(0.92-1.74 0.133
BMI
Not malnourished 1.0 - 1.0 -
Malnourished 1.72(1.27-2.31) < 0.001 0.80(0.92-1.75) 0.492
On HAART
No 1.0 - 1.0 -
Yes 0.99(0.81-1.21) 0.918 0.68(0.48-0.95) 0.027
Time on HAART
Less than 1 year 1.0 - 1.0 -
One year or more 0.47(0.37-0.60) < 0.001 1.32(0.83-2.20) O.221
AIDS
No 1.0 - 1.0 -
Yes 1.86(1.45-2.39) < 0.001 0.72(0.49-1.04) 0.087
CD4
< 200 1.0 - 1.0 -
≥ 200 0.52(0.41-0.65) < 0.001 2.62(1.44-4.78) 0.002
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Page 7 of 10According to the literature, a fundamental question
relating to the control of HIV/tuberculosis co-infection
is a higher degree of interaction between the action
taken to control the two diseases, as a way of achieving
a higher level of adherence on the part of patients to
screening for tuberculosis and the treatments available
[55]. This should extend beyond program coordination
and include point of health care delivery, where a multi-
disciplinary team should be present to carry out tuber-
culosis control activities when caring for patients with
HIV/AIDS.
The involvement of a multidisciplinary team is funda-
mental for the adequate running of a service, with each
component playing a specific role. A study conducted
among patients being attended at an adult emergency
unit, including those living with HIV, has shown that
triage, counseling and patient education are of special
importance [56]. According to this study, it was counsel-
ing that took up most of the time, reaching out not only
to patients, but also to family members and partners.
Tuberculosis counseling also involved the provision of
information on tuberculosis and HIV, and special atten-
tion was paid to making appointments, calling patients
and ensuring patients pay a return visit by giving them
a free bus ticket. Chaisson and colleagues [57] have
emphasized the importance of the nurses’ role, noting
an increase in adherence to TST from 37% to 74%,
when, in addition to a food vouchers, patients were
offered a consultation with a nurse. This study also
emphasized the importance of having a medical assistant
involved in the final interpretation and progress of each
case.
The present study has certain limitations due to its
design (cross-sectional), which may have caused some
associations due to reverse causality. Besides this, we
had to deal with the difficulties of an operational
research undertaken during the routine care of patients.
A selection bias can have occurred due to the difficulties
involved in accessing health services. However, health
care for people living with HIV in Brazil is good and in
Table 5 Multivariate Final Models for Not Taking TST and for TST ≥ 5 mm, RECIFE, 2007 - 2010
VARIABLES NOT TAKING TST TST ≥ 5m m
OR (CI 95%) p value OR (CI 95%) p value
Sex
Female 1 - -
Male 1.48(1.19-1.84) < 0.001 - -
Age
40 years or over 1 - -
Up to 39 years 1.28(1.04-1.58) 0.019 - -
Place of Residence
Recife 1 1
Metropolitan Region 0.90(0.72-1.12) 0.357 1.67(1.15-2.42) 0.006
Interior 1.80(1.31-2.47) < 0.001 1.00(0.54-1.87 0.975
Hospital attended
HUOC* 1 1
HCP* 1.55(1.25-1.92) < 0.001 2.03(1.40-2.95) < 0.001
Crack use
No 1 1
Yes 1.68(1.10-2.60) 0.020 3.48(1.76-6.90) < 0.001
Time on HAART
Less than 1 year 1 - -
One year or more 0.65(0.50-0.85) 0.002 - -
AIDS
No 1 - -
Yes 6.66(4.04-10.10) < 0.001 - -
CD4
< 200 1 1
≥ 200 0.70(0.54-0.91) 0.008 2.71(1.40-2.95) < 0.001
Years of schooling
≥ 10 years - - 1
Up to 9 years - - 1.80(1.25-2.60) 0.002
* HUOC - Oswaldo Cruz University Hospital; HCP - Correia Picanço Hospital;
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Page 8 of 10spite of working with a convenience sample of patients
being attended at two separate health centers, the sam-
ple size was robust enough to detect the differences
between the groups.
Read phonetically
Furthermore, the findings of this study may contribute
to a better understanding of the reasons why TB is the
leading cause of death amongst people living with HIV
in Brazil. Preventing TB in people living with HIV is
one of the biggest challenges in countries with a reason-
able prevalence of co-infected individuals.
Conclusions
Considering that the TST is recommended by the Brazi-
lian health authorities, the coverage for taking the test
TST was low. The most serious implication of this is that
the treatment for LTBI was carried out for the unidenti-
fied TST-positive patients who may consequently go on to
develop TB, and eventually die. It would be of great
importance to review decisions regarding the initiation of
LTBI treatment being conditional on the tuberculin skin
test.
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